PRODUCCIÓN CIENTÍFICA (CCUMEGLCEA)

A R T Í C U L O S

> Hernández-Montes J, Rocha-Zavaleta L, Monroy-García A, Weiss-Steider B, Zaragoza-Ortega M del C, Cruz-Talonia F, et al. Peripheral blood lymphocytes from low-grade squamous intraepithelial lesions patients recognize vaccine antigens in the presence of activated dendritic cells, and produced high levels of CD8 + IFNγ + T cells and low levels of IL-2 when induced to proliferate. Infectious Agents and Cancer. 29 de mayo de 2012;7(1):12.

> Hernández-Montes J, Monroy-García A, Gómez-Lim MA, Weiss-Steider B, la Rosa GP, Pérez-Saldana K, et al. A novel HPV 16 L1-based chimeric virus-like particle containing E6 and E7 seroreactive epitopes permits highly specific detection of antibodies in patients with CIN 1 and HPV-16 infection. Virol J. 9 de febrero de 2011;8:59.

> Hernández-Montes J, Paz de la Rosa G, Monroy-García A, Mora-García LM, Reynaga Peña CG, Weiss-Steider B, et al. An HPV 16 L1-based chimeric human papilloma virus-like particles containing a string of epitopes produced in plants is able to elicit humoral and cytotoxic T-cell activity in mice. Virology Journal.2009;

> Hernández-Montes J, Morán-García M de L, Duenas-González A, De la Cruz-Hernández E, Pérez-Cárdenas E, Weiss-Steider B, et al. Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acid. Journal of Translational Medicine. 27 de diciembre de 2006;4(1):14.

> Hernández-Montes J, Rocha-Zavaleta L, Ambrosio JP, Mora-García M de L, Cruz-Talonia F, Weiss-Steider B, et al. Detection of antibodies against a human papillomavirus (HPV) type 16 peptide that differentiate high-risk from low-risk HPV-associated low-grade squamous intraepithelial lesions. J Gen Virol. septiembre de 2004;85:2643-50.

> Monroy-García A, Weiss-Steider B, Hernández-Montes J, Ortiz-Navarrete VF, Bañuelos-Pánuco A, Acosta-Araujo A, et al. Identification of two homologous antigenic peptides derived from L1 HPV-16 and 18 proteins specific for the HLA-B*3901 allele. Archives of virology. 12 de agosto de 2002;147:1933-42.

> García AM, Ortíz-Navarrete VF, Mora-García ML, Flores-Borja F, Díaz-Quiñonez A, Isibasi-Araujo A, et al. Identification of peptides presented by HLA class I molecules on cervical cancer cells with HPV-18 infection. Immunol Lett. 15 de abril de 1999;67(3):167-77.

CAPÍTULO DE LIBROS

> Hernández-Montes J. Respuesta inmune en contra del virus de papiloma humano (VPH). Respuesta Inmune Contra El Virus de Papiloma Humano Bases para el desarrollo de vacunas contra el cáncer cérvico-uterino. Editorial Académica Española; 2012.

> Hernández-Montes J, Monroy-García A, Mora-García M de L. Cancer immunology and novel strategies for immunotherapy. Molecular Oncology Principles and Recent Advances. Bentham Science Publishers; 2012.

> Hernández-Montes J. Factor estimulador de células progenitoras (SCF). Las citocinas en la Hematopoyesis y el sistema inmunológico: Mecanismos Celulares y Moleculares. Primera. México, D.F.: Plaza y Valdés; 1999.

> Hernandez-Montes J, Monroy-Garcia A, Mora García M de L. Identification of epitopes from L1, E6, and E7 proteins of the HPV-16 and -18 types and its implication for diagnosis and treatment of cervical carcinoma. Advances in cancer. Manual Moderno /PUIS, UNAM.;

P A T E N T E S

> Uso del péptido IHSMNSTIL de la proteína L1 de HPV16 para diagnóstico y prevención de la infección por virus de papiloma humano. No de Registro: PCT/MX2005/000072. En trámite.